Exchange: NASDAQ·Updated 07:59 PM EDT

MRNA News

News
all
press releases
The Politics Of Measles
The Politics Of Measles Authored by Jeffrey A. Tucker via The Epoch Times, By the middle point of 20th-century American history, measles was widely considered a rite of passage for kids. You get it and you shake it off. You earn lifetime immunity. This was true of every generation...
Zero Hedge
More News
Wall Street Has Cooled on Moderna After Its Stock Jumped Over 5X. But Does the mRNA Leader Have More Room to Run?
Key PointsModerna's shares have pulled back since their most recent highs...
Nasdaq News: Markets
Why Is Recursion Pharmaceuticals (RXRX) Up 8.2% Since Last Earnings Report?
Recursion Pharmaceuticals (RXRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
BioNTech vs. Moderna: Which Is the Better Cancer Vaccine Stock to Buy Now?
Key PointsBioNTech and Moderna are no longer generating significant revenue from their coronavirus vaccines...
Nasdaq News: Markets
Does Moderna's mRNA Flu Shot Face a New Challenge From GSK?
MRNA's newly approved mFlusiva faces a potential challenge as GSK advances an mRNA flu vaccine targeting two viral proteins.
Zacks
Moderna's Cancer Vaccine Rally Sparks Rare Sell Rating and Projected 45% Stock Drop
Moderna's Cancer Vaccine Rally Sparks Rare Sell Rating and Projected 45% Stock Drop...
Yahoo! Finance: News
This Fund Bought Moderna Before It Nearly Tripled. See Its 2 New Stock Picks
This Fund Bought Moderna Before It Nearly Tripled. See Its 2 New Stock Picks...
Yahoo! Finance: News
This Sonoco Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Thursday
Analysts downgraded Ultragenyx, Moderna and Sonoco; targets fell for RARE and SON but rose for MRNA.read more...
Benzinga
CrowdStrike To Rally Over 15%? Here Are 10 Top Analyst Forecasts For Thursday
Analysts revised price targets for Ultragenyx, UiPath, Netskope, Snowflake, Magnite, Broadcom, CrowdStrike and Moderna; ratings largely maintained.read more...
Benzinga
GSK to Advance mRNA Influenza Vaccine Into Phase III Development
GSK to advance its mRNA flu vaccine into phase III after phase II study has shown stronger immune responses and good tolerability.
Zacks

Advertisement|Remove ads.